Qube Research & Technologies (QRT)
KLRS icon

Qube Research & Technologies (QRT)’s Kalaris Therapeutics KLRS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,103
Closed -$64.1K – 4226
2026
Q1 		$64.1K Buy
+11,103
New +$98.5K ﹤0.01% 3140
2025
Q1 		– Sell
-632
Closed -$6.11K – 3968
2024
Q4 		$6.11K Sell
632
-861
-58% -$13K ﹤0.01% 3285
2024
Q3 		$27.8K Sell
1,493
-1,934
-56% -$33.8K ﹤0.01% 2941
2024
Q2 		$57K Sell
3,427
-1,254
-27% -$22.1K ﹤0.01% 2720
2024
Q1 		$81.3K Sell
4,681
-3,885
-45% -$63.4K ﹤0.01% 3378
2023
Q4 		$134K Buy
+8,566
New +$338K ﹤0.01% 2989
2021
Q1 		– Sell
-272
Closed -$240K – 2501
2020
Q4 		$240K Buy
+272
New +$209K ﹤0.01% 1459

Other funds holding KLRS

Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KLRS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 11,103 shares — an estimated $64.1K sold.

Qube Research & Technologies (QRT) first reported a position in KLRS in Q4 2020 and held it in 7 quarters. The position peaked at $240K in Q4 2020. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 11,103 Kalaris Therapeutics shares in Q2 2026, an estimated $64.1K.
  • Qube Research & Technologies (QRT) first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 7 quarters.
  • Qube Research & Technologies (QRT)'s Kalaris Therapeutics position peaked at $240K in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.